Trial Profile
A Phase III trial comparing either COntinuous chemotherapy plus cetuximab or INtermittent chemotherapy with standard continuous palliative combination chemotherapy with oxaliplatin and a fluoropyrimidine in first line treatment of metastatic colorectal cancer
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 09 Dec 2021
Price :
$35
*
At a glance
- Drugs Cetuximab (Primary) ; Capecitabine; Fluorouracil; Folinic acid; Oxaliplatin
- Indications Adenocarcinoma; Colorectal cancer
- Focus Therapeutic Use
- Acronyms COIN
- 01 Nov 2021 Results of pooled analysis from MRC-COIN and COIN-B trials assessing Genome-wide association studies of toxicity published in the International Journal of Cancer
- 12 Jul 2021 Results assessing effect of anti-EGFR therapy on survival in different consensus molecular subtypes (CMSs) and stratified by primary tumour location retrospectively in two studies (COIN & PICCOLO), published in the British Journal of Cancer.
- 17 Jan 2021 Results of pooled analysis assessing tumor bulk as a predictive biomarker to anti-EGFR therapy by using data from two studies (COIN and COIN B) presented at the 2021 Gastrointestinal Cancers Symposium